KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema

Reuters

2025/10/07

KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema $(HAE)$. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573684988"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573684988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573684988?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573684988","market":"nz","top_or_hot":-1,"title":"KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a>. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-07 04:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a>. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDLc1k6wY:1","article_id":"2573684988","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573684988","pubTimestamp":1759780818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY, the First Oral On-Demand Treatment for Hereditary Angioedema. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on October 06, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"KalVista Pharmaceuticals宣布EKTERLY的积极临床数据和欧洲上市®，首个口服按需治疗遗传性血管性水肿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n    \n\n        KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema $(HAE)$. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}